open access

Vol 89, No 1 (2018)
Research paper
Published online: 2018-01-31
Get Citation

Does IGF-1 play a role in the biology of ovarian cancer?

Dominika Majchrzak-Baczmańska1, Andrzej Malinowski1, Ewa Głowacka1, Miłosz Wilczyński1
DOI: 10.5603/GP.a2018.0003
·
Pubmed: 29411341
·
Ginekol Pol 2018;89(1):13-19.
Affiliations
  1. Instytut Centrum Zdrowia Matki Polki, Łódź, Poland

open access

Vol 89, No 1 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-01-31

Abstract

Objectives: The aim of the study was to investigate serum concentrations of the insulin-like growth factor-1 in women with ovarian cancer and healthy controls, and to compare free IGF-1 levels with selected clinical and pathological param­eters. Correlation analysis was used to measure the following: IGF-1 concentration and Ca125; IGF-1 level and the height of the OC patients.

Material and methods: The study included 70 patients with OC and 50 healthy controls. Serum concentrations of free IGF-1 were measured in all subjects. Routine diagnostic tests (CBC and USG and Ca125) were performed.

Results: Significantly higher serum concentrations of free IGF-1 were found in the study group as compared to controls. No statistically significant relationships between IGF-1 serum concentrations and tumor differentiation, histological type, and disease stage were detected. No statistically significant correlations between IGF-1 and Ca125 level or between IGF-1 and growth of OC patients were found.

Conclusions: Serum IGF-1 participates in the etiopathogenesis of ovarian cancer in menstruating women, while local synthesis of this factor and other components of the autocrine loop of the IGF-1 system play a greater role in their post­menopausal peers.

Abstract

Objectives: The aim of the study was to investigate serum concentrations of the insulin-like growth factor-1 in women with ovarian cancer and healthy controls, and to compare free IGF-1 levels with selected clinical and pathological param­eters. Correlation analysis was used to measure the following: IGF-1 concentration and Ca125; IGF-1 level and the height of the OC patients.

Material and methods: The study included 70 patients with OC and 50 healthy controls. Serum concentrations of free IGF-1 were measured in all subjects. Routine diagnostic tests (CBC and USG and Ca125) were performed.

Results: Significantly higher serum concentrations of free IGF-1 were found in the study group as compared to controls. No statistically significant relationships between IGF-1 serum concentrations and tumor differentiation, histological type, and disease stage were detected. No statistically significant correlations between IGF-1 and Ca125 level or between IGF-1 and growth of OC patients were found.

Conclusions: Serum IGF-1 participates in the etiopathogenesis of ovarian cancer in menstruating women, while local synthesis of this factor and other components of the autocrine loop of the IGF-1 system play a greater role in their post­menopausal peers.

Get Citation

Keywords

ovarian cancer, insulin-like growth factor–1, carcinogenesis

Supp./Additional Files (1)
Tables
Download
25KB
About this article
Title

Does IGF-1 play a role in the biology of ovarian cancer?

Journal

Ginekologia Polska

Issue

Vol 89, No 1 (2018)

Article type

Research paper

Pages

13-19

Published online

2018-01-31

DOI

10.5603/GP.a2018.0003

Pubmed

29411341

Bibliographic record

Ginekol Pol 2018;89(1):13-19.

Keywords

ovarian cancer
insulin-like growth factor–1
carcinogenesis

Authors

Dominika Majchrzak-Baczmańska
Andrzej Malinowski
Ewa Głowacka
Miłosz Wilczyński

References (38)
  1. Majchrzak-Baczmańska D, Malinowski A. Does IGF-1 play a role in the biology of endometrial cancer? Ginekol Pol. 2016; 87(8): 598–604.
  2. Cao Z, Liu LZ, Dixon DA, et al. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal. 2007; 19(7): 1542–1553.
  3. Whitley BR, Beaulieu LM, Carter JC, et al. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol. 2007; 104(2): 470–479.
  4. Kuhn W, Schmalfeldt B, Reuning U, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer. 1999; 79(11-12): 1746–1751.
  5. Shen MR, Lin AC, Hsu YM, et al. Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem. 2004; 279(38): 40017–40025.
  6. Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007; 25(5): 346–354.
  7. Spentzos D, Cannistra SA, Grall F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007; 14(3): 781–790.
  8. Karasik A, Menczer J, Pariente C, et al. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994; 78(2): 271–276.
  9. Yee D, Morales FR, Hamilton TC, et al. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991; 51(19): 5107–5112.
  10. Peeters PHM, Lukanova A, Allen N, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer. 2002; 101(6): 549–554.
  11. Peeters PHM, Lukanova A, Allen N, et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007; 14(1): 81–90.
  12. Tas F, Karabulut S, Serilmez M, et al. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol. 2014; 35(4): 3125–3132.
  13. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(1): 2–19.
  14. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351(9113): 1393–1396.
  15. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003; 13(4): 113–170.
  16. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012; 9(4): e1001200.
  17. Gunnell D, Oliver SE, Donovan JL, et al. Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab. 2004; 89(1): 213–218.
  18. Lukanova A, Toniolo P, Lundin E, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer. 2002; 99(4): 603–608.
  19. Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev. 2001; 10(5): 443–452.
  20. Ovesen P, Vahl N, Fisker S, et al. Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab. 1998; 83(5): 1662–1667.
  21. Gleeson HK, Shalet SM. GH responsiveness varies during the menstrual cycle. Eur J Endocrinol. 2005; 153(6): 775–779.
  22. Thierry van Dessel HJ, Chandrasekher Y, Yap OW, et al. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab. 1996; 81(3): 1224–1231.
  23. Juul A, Scheike T, Pedersen AT, et al. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Hum Reprod. 1997; 12(10): 2123–2128.
  24. Guidoux S, Garnier PE, Schimpff RM. Effect of the variations of female sex hormones during the menstrual cycle upon serum somatomedin and growth-promoting activity. Horm Res. 1986; 23(1): 31–37.
  25. Flyvbjerg A, Mogensen O, Mogensen B, et al. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 1997; 82(7): 2308–2313.
  26. Waksmański B, Dudkiewicz J, Kowalski T. Changes in insulin-like growth factor I, 17-b-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours. Med Sci Monit. 2001; 7(5): 919–923.
  27. Dal Maso L, Augustin LSA, Franceschi S, et al. Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology. 2004; 67(3-4): 225–230.
  28. Baron-Hay S, Boyle F, Ferrier A, et al. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 2004; 10(5): 1796–1806.
  29. Serin IS, Tanriverdi F, Yilmaz MO, et al. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol. 2008; 24(3): 117–121.
  30. Tworoger SS, Lee IM, Buring JE, et al. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev. 2007; 16(8): 1691–1695.
  31. Zhang L, Curhan GC, Forman JP. Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women. J Hypertens. 2011; 29(2): 229–235.
  32. van Bunderen CC, Oosterwerff MM, van Schoor NM, et al. Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study. Eur J Endocrinol. 2013; 168(3): 393–401.
  33. Sesti G, Sciacqua A, Cardellini M, et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care. 2005; 28(1): 120–125.
  34. Rajpathak SN, Gunter MJ, Wylie-Rosett J, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009; 25(1): 3–12.
  35. Decensi A, Bonanni B, Baglietto L, et al. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res. 2004; 10(13): 4389–4397.
  36. Shah NG, Bhatavdekar JM, Doctor SS, et al. Circulating epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) in patients with epithelial ovarian carcinoma. Neoplasma. 1994; 41(5): 241–243.
  37. Wang Q, Liu Li, Li H, et al. Genetic and dietary determinants of insulin-like growth factor (IGF)-1 and IGF binding protein (BP)-3 levels among Chinese women. PLoS One. 2014; 9(10): e108934.
  38. Conover CA, Hartmann LC, Bradley S, et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res. 1998; 238(2): 439–449.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl